Perampanel serum concentrations in adults with epilepsy: Effect of dose, age, sex, and concomitant anti-epileptic drugs

Therapeutic Drug Monitoring

Volumn 38, Issue 3, 2016, Pages 358-364

  Patsalos, Philip N ^a   Gougoulaki, Marilia ^a   Sander, Josemir W ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Carbamazepine; New anti epileptic drug; Oxcarbazepine; Pharmacokinetic drug drug interactions

Indexed keywords

PERAMPANEL; PHENYTOIN; TOPIRAMATE; ANTICONVULSIVE AGENT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG POTENTIATION; EPILEPSY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MONOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; ADOLESCENT; AGE; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG INTERACTION; METABOLISM; MIDDLE AGED; PROCEDURES; SEX DIFFERENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PYRIDONES; RETROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 84953327583     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000274     Document Type: Article

References (28)

1. Leddingham DRM, Patsalos PN. Perampanel: what is its place in the management of epilepsy? Neurol Ther. 2013;2:13-24.
2. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr. 2011;11:56-63.
3. Rogawski MA, Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA receptor antagonist. Acta Neurol Scand Supp. 2013;197:19-24.
4. Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56:12-27.
5. Laurenza A, Ferry J, Hussein Z. Population Pharmacokinetics and pharmacodynamics of perampanel: A pooled analysis from three phase III trials [abstract No. 2.231 plus poster]. Paper presented at: 65th Annual Meeting of the American Epilepsy Society; December 2-6, 2011; Baltimore, M.D.
6. Vazquez B, Yang H, Williams B, et al. Perampanel efficacy and safety by gender: subanalysis of phase III randomized clinical studies in subjects with partial seizures. Epilepsia. 2015;56:e90-e94.
7. Gidal BE, Ferry J, Majid O, et al. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures. Epilepsia. 2013;54:1490-1497.
8. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology. 2012;79:589-596.
9. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial onset seizures: results of randomized global phase III study 305. Epilepsia. 2013;54:117-125.
10. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study306: adjunctive perampanel for refractory partial-onset seizures. Neurology. 2012;78:1408-1415.
11. Johannessen Landmark C, Patsalos PN. Methodologies used to identify and characterize interactions among antiepileptic drugs. Exp Rev Clin Pharmacol. 2012;5:281-292.
12. EMA Guidelines on Bioanalytical Method Validation. Available at: http://www.ema.europe.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf. Accessed September 2, 2013.
13. FDA. Guidance for Industry: Bioanalytical Method Validation. Available at: http://www.fda.gov/downloads/Drugs/.../Guidances/ucm070107. pdf. Accessed September 2, 2013.
14. Wu T, Nagaya Y, Hanada T. Pharmacodynamic and pharmacokinetic interactions of perampanel and other antiepileptic drugs in a rat amygdala kindling model. Seizure. 2014;23:732-739.
15. Gidal BE, Laurenza A, Hussein Z, et al. Perampanel efficacy and tolerability with enzyme-inducing AEDs in patients with epilepsy. Neurology. 2015;84:1972-1980.
16. Patsalos PN, Froscher W, Pisani F, et al. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365-385.
17. Patsalos PN, Berry DJ, Bourgeois BFD, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia. 2008;49:1239-1276.
18. Wen X, Wang JS, Kivisto KT, et al. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52: 547-553.
19. Gidal BE, Sheth R, Parnell J, et al. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res. 2003;57:85-93.
20. Löscher W. The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia. 2007;48: 1245-1258.
21. Markoula S, Teotonio R, Ratnaraj N, et al. Lacosamide serum concentrations in adult patients with epilepsy: the influence of gender, age, dose and concomitant antiepileptic drugs. Ther Drug Monit. 2014;36: 494-498.
22. May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit. 1999;21:175-181.
23. Bockbrader HN, Burger P, Knapp L, et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia. 2011;52:248-257.
24. Greenblatt DJ, Divoll M, Puri SK, et al. Clobazam kinetics in the elderly. Br J Clin Pharmacol. 1881;12:631-636.
25. Ibarra M, Vasquez M, Fagiolino P. Sex related differences on valproic acid pharmacokinetics after oral single dose. J Pharmacokinet Pharmacodyn. 2013;40:479-486.
26. Marino SE, Birnbaum AK, Leppik IE, et al. Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex. Clin Pharmacol Ther. 2012;91:483-488.
27. Smith GA, McKauge L, Dubertz D, et al. Factors influencing plasma concentrations of ethosuximide. Clin Pharmacokinet. 1979;4:38-52.
28. Perucca E, Cloyd J, Critchley D, et al. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilerpsia. 2008;49:1123-1141.